Zhang Financial LLC Makes New Investment in Jazz Pharmaceuticals PLC $JAZZ

Zhang Financial LLC purchased a new position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the first quarter, Holdings Channel reports. The institutional investor purchased 2,720 shares of the specialty pharmaceutical company’s stock, valued at approximately $514,000.

Other institutional investors have also recently made changes to their positions in the company. Ruffer LLP purchased a new position in Jazz Pharmaceuticals during the 4th quarter valued at about $2,425,000. Allianz Asset Management GmbH raised its holdings in shares of Jazz Pharmaceuticals by 68.2% in the 4th quarter. Allianz Asset Management GmbH now owns 598,832 shares of the specialty pharmaceutical company’s stock valued at $101,801,000 after purchasing an additional 242,892 shares in the last quarter. Capricorn Fund Managers Ltd purchased a new stake in shares of Jazz Pharmaceuticals in the 4th quarter worth approximately $1,700,000. Swedbank AB lifted its position in shares of Jazz Pharmaceuticals by 2.7% in the 4th quarter. Swedbank AB now owns 1,102,974 shares of the specialty pharmaceutical company’s stock worth $187,506,000 after purchasing an additional 28,882 shares during the period. Finally, Daiwa Securities Group Inc. boosted its stake in shares of Jazz Pharmaceuticals by 274.6% during the fourth quarter. Daiwa Securities Group Inc. now owns 8,583 shares of the specialty pharmaceutical company’s stock valued at $1,459,000 after purchasing an additional 6,292 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, Director Heather Ann Mcsharry sold 2,000 shares of the business’s stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $241.00, for a total transaction of $482,000.00. Following the transaction, the director directly owned 18,449 shares in the company, valued at $4,446,209. The trade was a 9.78% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Neena M. Patil sold 1,200 shares of the company’s stock in a transaction dated Wednesday, June 10th. The shares were sold at an average price of $231.83, for a total value of $278,196.00. Following the transaction, the executive vice president directly owned 51,549 shares in the company, valued at $11,950,604.67. This represents a 2.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 13,098 shares of company stock valued at $3,131,906. Corporate insiders own 4.10% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on JAZZ shares. Wells Fargo & Company lifted their price objective on shares of Jazz Pharmaceuticals from $265.00 to $285.00 and gave the company an “overweight” rating in a report on Tuesday. Leerink Partners upped their target price on Jazz Pharmaceuticals from $215.00 to $225.00 and gave the stock an “outperform” rating in a report on Wednesday, April 22nd. Weiss Ratings raised Jazz Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, June 29th. Deutsche Bank Aktiengesellschaft lifted their price target on Jazz Pharmaceuticals from $250.00 to $270.00 and gave the company a “buy” rating in a report on Thursday, July 9th. Finally, Bank of America boosted their price target on Jazz Pharmaceuticals from $281.00 to $307.00 and gave the stock a “buy” rating in a research report on Wednesday, June 10th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, Jazz Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $256.44.

Jazz Pharmaceuticals Stock Up 2.2%

Shares of Jazz Pharmaceuticals stock opened at $247.53 on Friday. The company has a quick ratio of 1.85, a current ratio of 2.04 and a debt-to-equity ratio of 0.95. The company has a market cap of $15.55 billion, a P/E ratio of -12,370.31, a PEG ratio of 0.22 and a beta of 0.32. The firm’s 50 day moving average price is $235.11 and its 200-day moving average price is $200.42. Jazz Pharmaceuticals PLC has a 52-week low of $105.00 and a 52-week high of $250.49.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 EPS for the quarter. The company had revenue of $1.07 billion during the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. On average, sell-side analysts predict that Jazz Pharmaceuticals PLC will post 21.9 EPS for the current fiscal year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.